Healthcare Pricing & PBMs: A new look at how cost-plus formulas and rebate math can distort drug and pharmacy benefit decisions highlights why “a formula is not a guarantee,” with PBMs shifting toward more cost-based reimbursement while pharmacists translate complexity into patient care. Hospital Value-Chain Scrutiny: Max Healthcare’s chairman argues hospital pricing should be judged across the full care value chain—not just individual items—amid legal and regulatory pressure over steep markups. Biosimilars Under Pressure: An interview explains why rebate structures and formulary control can keep biosimilars from gaining ground, even when clinical differences are modest. Community CAR-T Scaling: Reimagine Care discusses how remote monitoring plus AI triage aims to help community practices scale CAR-T programs without ballooning staffing. AI in Revenue Cycle: AKASA launches “autonomous” mid-cycle coding to fully code inpatient cases in about 90 seconds after discharge. Diabetes Supply Update: Novo Nordisk plans to withdraw Levemir insulin in all forms by end of 2026, with guidance for switching to alternatives. Oncology Pipeline Highlights: Multiple trial updates span oral SERDs, myeloma triplet comparisons, and RAS G12D PDAC combination studies, alongside early results for localized cisplatin patches in oral cancer. Aged Care Leadership: Aged Care Decisions appoints a new CEO as it continues helping families navigate placement options. Workforce & Wellness: India’s Ayush services sector is reported to support 1.76M livelihoods, with women making up 43% of the workforce.